Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

"Longer follow-ups after the pandemic are needed to investigate persistent brain aging effects and their long-term ...

To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers. Did ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the ...

This was the stock's second consecutive day of losses.

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

Bristol-Myers Squibb’s shares (currently trading at $46.80) have posted a disappointing 18% loss, well below the S&P 500’s ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

American multinational biopharmaceutical firm Bristol Myers Squibb (BMS) has hosted a high-level professional forum in partnership with the U.S. Embassy in Hungary, titled “Innovating Together for ...